Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
The Lancet. Gastroenterology & Hepatology
|
January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, et al.
Nature Medicine
|
May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Xiangyu Gao, Ke Ji, Yongning Jia, et al.
The Lancet. Oncology
|
May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, et al.
Cell Reports. Medicine
|
November 28, 2023
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
Bo Zhang, Yan Song, Suxia Luo, et al.
JAMA
|
September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo, Jin Lu, Yuxian Bai, et al.
Med (New York, N.Y.)
|
June 13, 2024
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
Mingming He, Zhiqiang Wang, Jin Lu, et al.
Cancer Communications (London, England)
|
October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng, Tianshu Liu, Jia Wei, et al.
Nature Communications
|
February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Jianming Xu, Yi Li, Qingxia Fan, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng, Junsheng Wang, Jin Xia, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
The Lancet. Gastroenterology & Hepatology
|
January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, et al.
Nature Medicine
|
May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Xiangyu Gao, Ke Ji, Yongning Jia, et al.
The Lancet. Oncology
|
May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, et al.
Cell Reports. Medicine
|
November 28, 2023
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
Bo Zhang, Yan Song, Suxia Luo, et al.
JAMA
|
September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo, Jin Lu, Yuxian Bai, et al.
Med (New York, N.Y.)
|
June 13, 2024
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
Mingming He, Zhiqiang Wang, Jin Lu, et al.
Cancer Communications (London, England)
|
October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng, Tianshu Liu, Jia Wei, et al.
Nature Communications
|
February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Jianming Xu, Yi Li, Qingxia Fan, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng, Junsheng Wang, Jin Xia, et al.
Page
of 11